Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons.

The comparison included separate treatment groups

Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein decreases seen in morphine-tolerant midbrain were not observed in the combination group. The inference depends on the comparator, not simply whether a protein amount was high or low.

The spinal findings differed

Combination-treated animals had higher selected receptor-protein amounts in spinal cord than morphine-tolerant animals. CB1 protein also showed a different pattern in spinal cord and midbrain. Protein abundance is not itself a direct measurement of receptor signaling or a clinical pain outcome.

The causal interpretation remained incomplete

The findings were associated with a short-term antinociceptive profile discussed by the authors. An association between receptor regulation and tolerance does not prove that the protein pattern alone caused the behavioral result or that it will persist during longer exposure.

Interpreting the evidence

The study supports specifying tissue, receptor class and comparison group. It does not establish a safe human combination, a durable opioid-sparing regimen or absence of dependence and other adverse effects. Mouse receptor proteins cannot replace clinical efficacy and safety evidence.

Related reading: interpreting cannabis tolerance claims.

Research reference

Cichewicz DL; Haller VL; Welch SP (2001). Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us